In most Enterobacterales infections, including common urinary pathogens, which treatment approach is described as appropriate?

Prepare for the CAMLPR Microbiology Test. Utilize flashcards and engaging multiple-choice questions, each equipped with descriptions and explanations. Ready yourself for an excellent performance!

Multiple Choice

In most Enterobacterales infections, including common urinary pathogens, which treatment approach is described as appropriate?

When treating Enterobacterales infections, it’s important to choose antibiotics that remain effective in the face of beta-lactamase enzymes and that suit the infection site. Nitrofurantoin is particularly useful for urinary isolates because it achieves very high concentrations in the urine and stays active against many common uropathogens, making it a good option for uncomplicated bladder infections. Ceftriaxone offers reliable broad coverage for Enterobacterales in more systemic or complicated scenarios, including urinary infections that may involve the upper tract or other sites. If an ESBL-producing organism is suspected or confirmed, carbapenems are preferred because ESBLs break down many penicillins and cephalosporins, whereas carbapenems resist those enzymes and remain effective. Amoxicillin is typically avoided because widespread beta-lactamase production by Enterobacterales renders it ineffective for most infections caused by these bacteria. Other agents like aztreonam, aminoglycosides, or fluoroquinolones have roles in specific situations, but the described approach—using ceftriaxone and nitrofurantoin for urinary isolates and reserving carbapenems for ESBL producers—provides a robust strategy for the common Enterobacterales urinary pathogens.

When treating Enterobacterales infections, it’s important to choose antibiotics that remain effective in the face of beta-lactamase enzymes and that suit the infection site. Nitrofurantoin is particularly useful for urinary isolates because it achieves very high concentrations in the urine and stays active against many common uropathogens, making it a good option for uncomplicated bladder infections. Ceftriaxone offers reliable broad coverage for Enterobacterales in more systemic or complicated scenarios, including urinary infections that may involve the upper tract or other sites. If an ESBL-producing organism is suspected or confirmed, carbapenems are preferred because ESBLs break down many penicillins and cephalosporins, whereas carbapenems resist those enzymes and remain effective.

Amoxicillin is typically avoided because widespread beta-lactamase production by Enterobacterales renders it ineffective for most infections caused by these bacteria. Other agents like aztreonam, aminoglycosides, or fluoroquinolones have roles in specific situations, but the described approach—using ceftriaxone and nitrofurantoin for urinary isolates and reserving carbapenems for ESBL producers—provides a robust strategy for the common Enterobacterales urinary pathogens.

More practice questions